Slide 1: Intimation of Investor Presentation to BSE Limited
21/08/2026 The Deputy Manager Corporate Relationship Department BSE Limited P. J. Towers, Dalal Street, Mumbai – 400001 Scrip Code: 544529 ISIN: INE15XJ01010 Dear Sir/Madam, Sub: Intimation of Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulat
Slide 2: Investor Presentation
INVESTOR PRESENTATION We Deliver Quality & Innovation to Redefine Human Lives
Slide 3: Disclaimer
This communication is being issued by Aptus Pharma ltd.("the Company") for general information purposes only. The information contained herein is based on management's current expectations and beliefs and is subject to change without notice. Certain statements in this document may be forward-looking
Slide 4: Leader vision and Key USPs of APPL
Leader vision At Aptus Pharma Limited, our vision is to build a future where quality healthcare solutions are accessible, reliable, and driven by innovation. We aspire to be a globally trusted pharmaceutical organization, recognized for excellence, integrity, and sustainable growth. Our focus is on
Slide 5: Table of Contents
Table of Contents Company Overview Industry Overview Business Overview Financial Performance Way Ahead Thank You
Slide 6: Company Overview
Company Overview Aptus Pharma Ltd., established in 2010, is a fast-growing player in India's pharmaceutical sector, driven by a strong focus on brand building and market expansion. The company is engaged in developing and promoting high-quality pharmaceutical brands across diverse therapeutic segmen
Slide 7: Core Values and Core Purpose
Core Values Core Purpose BRAND We Deliver PROMISE Quality & "We committed to healthcare Innovation and healthcare professionals." Aptus Pharma pledges to To Redefine uphold the highest standards in contributing to the well-being Human Lives of individuals and supporting the healthcare community.
Slide 8: Business Overview
BUSINESS OVERVIEW
Slide 9: Business Structure & Verticals
25,000+ v Business Structure & Verticals Retailers 250+ Pharma Formulation Formulations across The Pharma Formulation vertical will remain a core revenue-generating business of Aptus Pharma. The business model is primarily focused on multiple therapies promoting branded generic formulations through
Slide 10: Journey / Key Milestones
Journey / Key Milestones 2010 2011–2016 2016–2020 2021–2025 2025 - 2026 Incorporation of Aptus Early Growth Phase Portfolio & Footprint Scaling & Strengthening Listed on BSE SME Platform Pharma Limited Expansion • Strengthening • Started operations with 11 • Product portfolio governance, transparenc
Slide 11: Our Leadership & Management
Our Leadership & Management • Associated with Aptus since inception TEJASH M. HATHI • Over two decades of extensive experience in the pharmaceutical industry Managing Director • Leads corporate strategy and growth initiatives and Promoter GHANSHYAM V. • 15+ years industry experience PANSURIYA • Resp
Slide 12: Our Leadership & Management
Our Leadership & Management • Practicing consultant dermatologist with over 20 years of clinical experience CHETAN S. LALSETA • Holds M.B.B.S. and M.D. (Skin & V.D.) from Saurashtra University Non-Executive Director • Associated with leading hospitals including Wockhardt Hospital and Sterling Hospit
Slide 13: Business Process Flow
Business Process Flow Demand Selection of ' Estimation of | Manufacturing 5 * hase Ord Product Facility urchase Order Manufacturing Quality 5 resulta supply | of Products Approvals ystem powering final sales growth
Slide 14: Manufacturing & Quality Control
Manufacturing & Quality Control The Company follows an asset-light contract manufacturing model and does not own manufacturing facilities. It has entered into contractual manufacturing arrangements with WHO-GMP-certified manufacturing units under various arrangements. The Company has formal loan and
Slide 15: Key Therapeutic Solutions
RESPIRATORY MEDICINE ANTI- NEUROPSYCHIATRIC ET RDIOVAGEULAR ANTIDIABETIC INFLAMMATORY MEDICINE Preece MEDICINE — CRITICALCARE AYUSH SKIN CARE HAIR CARE PRODUCTS PRODUCT PRODUCT PRODUCT
Slide 16: Pharma Formulations and Prescription Brands; OTC & Wellness Brands
Pharma Formulations and Prescription Brands OTC & Wellness Brands
Slide 17: Industry Overview
INDUSTRY OVERVIEW
Slide 18: Global Pharmaceutical Industry
Global Pharmaceutical Industry Global Pharmaceutical Industry Continues to Expand on Ageing Population, Chronic Diseases & Innovation ~$1.7 >$2.3 ~6-7% v Trillion v Trillion v Global Pharma Expected Market by 2030 CAGR Market Growth Drivers v Rising ageing Increasing prevalence Healthcare spending S
Slide 19: India – Pharmacy of the World
India – Pharmacy of the World India is Emerging as a Key Global Pharmaceutical Hub Key Statistics • 3rd largest pharmaceutical producer by volume • Supplies 20% of global generic medicines • Largest number of USFDA-approved plants outside US • Exports medicines to 200+ countries • Pharma exports exc
Slide 20: Financial Performance
LLJ O 2 <x = oc O Li. oc LLJ a FINANCIAL
Slide 21: Managing Director's Statement – Financial Strength
Managing Director’s Statement – Financial Strength Our strong FY26 performance reflects the growing financial strength of Aptus Pharma. With 89.6% revenue growth and 49.1% PAT growth, we have built a solid platform for the next phase of expansion. Going forward, we remain focused on profitable growth,
Slide 22: Key Highlights & Achievements (F.Y. 2025-26)
Key Highlights & Achievements (F.Y. 2025-26) 24,670.81 lakh (+89.59% YoY) 2750.32 lakh (+57.73% YoY) 2461.99 lakh (+49.05% YoY) ! il ! EP 1 1 all Revenue doubled to ' EBITDA at ' PAT at i] i] Distribution network: 25,000+ retailers & 200+ distributors Expanded portfolio to 250+ formulations Strong p
Slide 23: H2 FY26 Profit & Loss Statement
H2 FY26 H2 FY26 ProfitProfit & Loss&Statement Loss Statement Particulars H2 FY26 H2 FY25 Y/Y H1 FY26 Q/Q Revenue from Operations 32.20 14.80 117.5% 14.38 123.9% Cost of Materials Consumed 0.00 0.00 0.00 Purchase of Stock - in - Trade 18.77 6.87 9.11 Changes in Inventories (3.22) (1.53) (3.29) Gross Pr
Slide 24: FY26 Profit & Loss Statement
FY26 Profit & Loss Statement FY26 FY25 Y/Y Revenue from Operations 46.57 24.56 89.7% Cost of Materials Consumed 0.00 0.00 Purchase of Stock - in - Trade 27.88 12.67 Changes in Inventories (6.51) (3.63) Gross Profit 25.20 15.52 62.4% Gross Profit % 54.1% 63.2% Employee Benefits Expenses 5.21 3.57 Other E
Slide 25: Balance Sheet as on 31st March 2026
Balance Sheet as on 31st March 2026 As on As on As on As on Total Equity & Liabilities Total Assets 31 st Mar’26 31 st Mar’25 st 31 Mar’26 st 31 Mar’25 Shareholders Funds 23.35 6.97 Non Current Assets 8.30 2.18 Share Capital 6.86 5.00 Property, plant & Equipment and Intangible Assets Reserves and Su
Slide 26: Key Financial Highlights
Key Financial Highlights Revenue from Operations EBITDA & EBITDA Margin PAT & PAT Margin 117% 56% 60% 32.20 4.49 2.87 20.51% 12.10% 12.10% 2.88 19.40% 2.95 1.75 14.00% 1.79 14.80 14.38 8.91% H2 FY25 H1 FY26 H2 FY26 H2 FY25 H1 FY26 H2 FY26 H2 FY25 H1 FY26 H2 FY26 Revenue from Operations EBITDA & EBIT
Slide 27: Way Ahead
WAY AHEAD
Slide 28: Strategic Growth Roadmap 2028–2029
Strategic Growth Roadmap 2028–2029 Manufacturing Expansion LADAKH Pan India by (Proposed by March 2028) March 2029 Global Expantion JAMMU & KASHMIR HIMACHAL BY MARCH - 2028 PRADESH UTTARAKHAND ARUNACHAL PUNJAB PRADESH SIKKIM ASIA HARYANA • UAE • Malaysia RAJASTHAN ASSAM NAGALAND • Myanmar UTTER PRAD
Slide 29: Awards & Certifications
Awards & Certifications We are committed to maintaining the highest standards of quality, safety, and excellence in the pharmaceutical industry. Our achievements, awards, and certifications reflect our dedication to innovation, customer satisfaction, and regulatory compliance. With a strong focus on in
Slide 30: Thank You
Thank You Aptus Pharma Ltd. AdfactorsPR Pvt. Ltd. Mr. Tejash Hathi Mr. Rahul Trivedi Managing Director Rahul.trivedi@adfactorspr.com http://www.aptus-pharma.com/ Mr. Vishal Bhalada Vishal.Bhalada@adfactorspr.com Mr. Vivek Sahu Vivek.sahu@adfactorspr.com